Research Papers:

FoxM1 is a promising candidate target in the treatment of breast cancer

Xiao-Feng Lu, De Zeng, Wei-Quan Liang, Chun-Fa Chen, Shu-Ming Sun and Hao-Yu Lin _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:842-852. https://doi.org/10.18632/oncotarget.23182

Metrics: PDF 1716 views  |   HTML 2648 views  |   ?  


Xiao-Feng Lu1,*, De Zeng2,*, Wei-Quan Liang1, Chun-Fa Chen1, Shu-Ming Sun1 and Hao-Yu Lin1

1Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China

2Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China

*These authors contributed equally to this work

Correspondence to:

Hao-Yu Lin, email: [email protected]

Keywords: FoxM1, breast cancer; prognostic values

Received: August 28, 2017     Accepted: November 16, 2017     Published: December 12, 2017


Forkhead box protein M1(FoxM1) is a member of forkhead superfamily transcription factors. Emerging evidences have progressively contributed to our understanding on a central role of FoxM1 in human cancers. However, perspectives on the function of FoxM1 in breast cancer (BC) remain conflicting, and mostly were from basic research. Here, we explored the expression profile and prognostic values of FoxM1 based on analysis of pooled clinical datasets derived from online accessible databases, including ONCOMINE, Breast Cancer Gene-Expression Miner v4.0, and Kaplan-Meier plotter. It was found that, FoxM1 mRNA expression was significantly higher in breast tumor versus normal control. FoxM1expression profile presented a distinct pattern in different molecular subtypes of BC patients. Higher expression of FoxM1 was correlated to low mRNA expression of estrogen receptor 1 (ESR1), erb-B2 receptor tyrosine kinase 2 (ERBB2), and was inversely associated with the expression of classical luminal regulators forkhead box protein A1 (FoxA1) and GATA binding protein 3 (GATA3). Elevated FoxM1 expression predicted shorter distance metastasis free survival (DMFS) in BC patients, particularly with estrogen receptor (ER) positive and Luminal A, Luminal B subtypes of BC. More interestingly, elevated FoxM1 expression predicted poor survival in breast cancer patients, especially in the ER (+), progesterone receptor (PR) (+) subgroups and BC patients received adjuvant chemotherapy only or treated with tamoxifen only. These results implied that FoxM1 is an essential prognostic factor and promising candidate target in the treatment of breast cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23182